Alan Johnson

Summary

Affiliation: Health Protection Agency
Country: UK

Publications

  1. doi request reprint Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, HPA Health Protection Services Colindale, NW9 5EQ, London, UK
    J Med Microbiol 62:499-513. 2013
  2. doi request reprint Fidaxomicin: a new option for the treatment of Clostridium difficile infection
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Health Protection Agency Centre for Infections, London NW9 5EQ, UK
    J Antimicrob Chemother 67:2788-92. 2012
  3. doi request reprint Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, HPA Centre for Infections, Colindale, London NW9 5EQ, UK
    J Antimicrob Chemother 67:802-9. 2012
  4. ncbi request reprint Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, Colindale, London NW9 5HT, UK
    J Antimicrob Chemother 52:953-60. 2003
  5. ncbi request reprint Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic
    Alan P Johnson
    Health Protection Agency Centre for Infections, Department of Healthcare Associated Infection and Antimicrobial Resistance, 61 Colindale Avenue, London NW9 5EQ, UK
    Curr Opin Investig Drugs 8:168-73. 2007
  6. ncbi request reprint Outpatient consumption of antibiotics is linked to antibiotic resistance in Europe: results from the European Surveillance of Antimicrobial Consumption
    Alan Johnson
    Health Protection Agency Centre for Infections, London, United Kingdom
    Euro Surveill 10:E050224.5. 2005
  7. ncbi request reprint Surveillance and epidemiology of MRSA bacteraemia in the UK
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Communicable Disease Surveillance Centre, HPA Centre for Infections, Colindale, London NW9 5EQ, UK
    J Antimicrob Chemother 56:455-62. 2005
  8. ncbi request reprint Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Communicable Disease Surveillance Centre, HPA Centre for Infections, Colindale, London NW9 5EQ, UK
    Int J Antimicrob Agents 25:539-41. 2005
  9. ncbi request reprint Antibiotic resistance in the intensive care unit setting
    Alan P Johnson
    Health Protection Agency, Antibiotic Resistance Monitoring and Reference Laboratory, Specialist and Reference Microbiology Division, Colindale, London, NW9 5 HT, UK
    Expert Rev Anti Infect Ther 1:253-60. 2003
  10. ncbi request reprint Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency, Specialist and Reference Microbiology Division, Colindale, London NW9 5HT, UK
    Int J Antimicrob Agents 24:315-9. 2004

Detail Information

Publications55

  1. doi request reprint Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, HPA Health Protection Services Colindale, NW9 5EQ, London, UK
    J Med Microbiol 62:499-513. 2013
    ..The spread of NDM illustrates that antibiotic resistance is a public health problem that transcends national borders and will require international cooperation between health authorities if it is to be controlled...
  2. doi request reprint Fidaxomicin: a new option for the treatment of Clostridium difficile infection
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Health Protection Agency Centre for Infections, London NW9 5EQ, UK
    J Antimicrob Chemother 67:2788-92. 2012
    ..difficile NAP1/B1/027 strain. The introduction of fidaxomicin extends the options for the treatment of CDI and may help to reduce the burden of this disease if fewer patients have recurrence of infection...
  3. doi request reprint Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, HPA Centre for Infections, Colindale, London NW9 5EQ, UK
    J Antimicrob Chemother 67:802-9. 2012
    ..It is to be hoped that based on the English experience of mandatory surveillance, other countries will consider the implementation of similar schemes, not only for MRSA but for other pathogens of public health importance...
  4. ncbi request reprint Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, Colindale, London NW9 5HT, UK
    J Antimicrob Chemother 52:953-60. 2003
    ..To determine the epidemiological relationship between pneumococci of serotype 9V, with reduced susceptibility to ciprofloxacin, penicillin and erythromycin, referred to the Reference Laboratory during 1997-2001...
  5. ncbi request reprint Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic
    Alan P Johnson
    Health Protection Agency Centre for Infections, Department of Healthcare Associated Infection and Antimicrobial Resistance, 61 Colindale Avenue, London NW9 5EQ, UK
    Curr Opin Investig Drugs 8:168-73. 2007
    ..A phase IIb/III clinical trial of OPT-80 in patients with CDAD is underway...
  6. ncbi request reprint Outpatient consumption of antibiotics is linked to antibiotic resistance in Europe: results from the European Surveillance of Antimicrobial Consumption
    Alan Johnson
    Health Protection Agency Centre for Infections, London, United Kingdom
    Euro Surveill 10:E050224.5. 2005
  7. ncbi request reprint Surveillance and epidemiology of MRSA bacteraemia in the UK
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Communicable Disease Surveillance Centre, HPA Centre for Infections, Colindale, London NW9 5EQ, UK
    J Antimicrob Chemother 56:455-62. 2005
    ..Surveillance and control of MRSA infection continue to be high profile and further developments to the mandatory surveillance system in England are likely in the near future...
  8. ncbi request reprint Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Communicable Disease Surveillance Centre, HPA Centre for Infections, Colindale, London NW9 5EQ, UK
    Int J Antimicrob Agents 25:539-41. 2005
    ..8%, 5.4% and 13% of the isolates, respectively. These results show that the large majority of pneumococci were susceptible to moxifloxacin in 2003, the year when it was licensed for clinical use in the UK...
  9. ncbi request reprint Antibiotic resistance in the intensive care unit setting
    Alan P Johnson
    Health Protection Agency, Antibiotic Resistance Monitoring and Reference Laboratory, Specialist and Reference Microbiology Division, Colindale, London, NW9 5 HT, UK
    Expert Rev Anti Infect Ther 1:253-60. 2003
    ....
  10. ncbi request reprint Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency, Specialist and Reference Microbiology Division, Colindale, London NW9 5HT, UK
    Int J Antimicrob Agents 24:315-9. 2004
    ..Daptomycin MICs were < or =2 and < or =4 mg/l for Enterococcus faecalis and Enterococcus faecium, respectively...
  11. ncbi request reprint Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar
    Alan P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency, Specialist and Reference Microbiology Division, Colindale, London NW9 5HT, UK
    J Antimicrob Chemother 53:860-2. 2004
    ....
  12. ncbi request reprint Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria
    Alan Johnson
    Health Protection Agency, Centre for Infections, Department of Healthcare Associated Infection and Antimicrobial Resistance, London, UK
    Future Microbiol 1:255-65. 2006
    ..Emergence of resistance to daptomycin has been reported, highlighting the need for prospective surveillance to determine the extent of this potential problem...
  13. ncbi request reprint Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Health Protection Agency Centre for Infections, London, NW9 5EQ, UK
    J Infect 55:394-9. 2007
    ....
  14. doi request reprint Enhanced surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland
    A P Johnson
    Department of Healthcare Associated Infections and Antimicrobial Resistance, HPA Centre for Infections, London NW9 5EQ, UK
    Arch Dis Child 95:781-5. 2010
    ..To determine the incidence and demographic features of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in children in the UK and Ireland and to characterise MRSA isolated from cases...
  15. doi request reprint New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile
    Alan P Johnson
    Health Protection Agency Centre for Infections, Department of Healthcare Associated Infection and Antimicrobial Resistance, London NW9 5EQ, UK
    Expert Opin Ther Pat 20:1389-99. 2010
    ..difficile to establish itself and produce disease. Currently, only vancomycin or metronidazole are recommended for treatment and many patients suffer from relapse on infection. Hence, there is a need for new treatment options...
  16. doi request reprint Methicillin-resistant Staphylococcus aureus: the European landscape
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, HPA Centre for Infections, Colindale, London, UK
    J Antimicrob Chemother 66:iv43-iv48. 2011
    ..Despite our increasing understanding of the epidemiology of MRSA in Europe, MRSA infections continue to pose a significant public health challenge...
  17. ncbi request reprint Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London NW9 5HT, UK
    J Antimicrob Chemother 45:225-30. 2000
    ..For all the species tested, the MICs of linezolid were unrelated to those of other antimicrobials. Linezolid appears to be a potentially useful drug for infections caused by gram-positive cocci...
  18. ncbi request reprint In-vitro activity of sanfetrinem against isolates of Streptococcus pneumoniae and Staphylococcus aureus
    A P Johnson
    Laboratory of Hospital Infection, Central Public Health Laboratory, Colindale, London, UK
    J Antimicrob Chemother 42:643-6. 1998
    ..06 mg/L). However, the MICs of sanfetrinem for isolates with methicillin MICs of 8-16 mg/L and > or = 32 mg/L were 0.25-1 mg/L and 8->32 mg/L, respectively...
  19. ncbi request reprint Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Colindale, London NW9 5HT, UK
    J Antimicrob Chemother 47:411-5. 2001
    ..Moxifloxacin may therefore be a useful drug for the treatment of patients with pneumococcal infections due to antibiotic-resistant strains or those with severe invasive disease...
  20. ncbi request reprint Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, NW9 5HT, London, UK
    Int J Antimicrob Agents 17:377-81. 2001
    ..The activity of moxifloxacin against pneumococci resistant to one or more first-line agent suggests it will have a useful therapeutic role, although its activity against highly ciprofloxacin resistant isolates seems marginal...
  21. ncbi request reprint Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London NW9 5HT, UK
    Eur J Clin Microbiol Infect Dis 21:751-4. 2002
    ..The linezolid-resistant isolates showed cross-resistance to the experimental oxazolidinone AZD2563, suggesting that oxazolidinone resistance might be a class effect...
  22. ncbi request reprint Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated?
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London UK
    J Hosp Infect 49:S3-11. 2001
    ..Empirical use of powerful newer agents may be justifiable in seriously ill patients in those settings, units and countries where there is a substantial background rate of resistance...
  23. ncbi request reprint Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK
    N Woodford
    Antibiotic Resistance Monitoring and Reference Laboratory, Specialist and Reference Microbiology Division Colindale, Health Protection Agency, London
    J Antimicrob Chemother 54:735-43. 2004
    ..e. MICs of cefotaxime > or = 8-fold higher than MICs of ceftazidime. Many were referred as being from community patients. We examined 291 CTX-M-producing isolates from the UK and investigated the genetic basis of their phenotype...
  24. ncbi request reprint Reliability of routine disc susceptibility testing by the British Society for Antimicrobial Chemotherapy (BSAC) method
    N A C Potz
    Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency, Specialist and Reference Microbiology Division, 61 Colindale Avenue, London NW9 5HT, UK
    J Antimicrob Chemother 53:729-38. 2004
    ..To ascertain the agreement between MICs determined at a central laboratory, and susceptible, intermediate and resistant categorizations based on zone diameters recorded at diagnostic laboratories using the BSAC standardized method...
  25. ncbi request reprint In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles
    D M Livermore
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT, UK
    Int J Antimicrob Agents 22:14-27. 2003
    ..Thus, if disc tests suggest that an isolate is marginally resistant to piperacillin/tazobactam and the drug is sought as therapy, it is recommended that MIC be determined with, e.g., an Etest...
  26. ncbi request reprint Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London, UK
    J Hosp Infect 54:179-87. 2003
    ..None of the isolates showed resistance to linezolid, with the MICs for the entire study population falling in the range of 0.5-4 mg/L...
  27. ncbi request reprint Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group
    C J Henwood
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale Avenue, London NW9 5HT, UK
    J Antimicrob Chemother 46:931-40. 2000
    ..Linezolid was the most potent agent tested against Gram-positive cocci, including multiresistant strains, and as such may prove a valuable therapeutic option for the management of Gram-positive infections in hospitals...
  28. ncbi request reprint Pazufloxacin Toyama Chemical Co
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London, NW9 5HT, UK
    Curr Opin Investig Drugs 1:52-7. 2000
    ..There is a licensing agreement with Welfide Corp (formerly Yoshitomi/The Green Cross Corp) in Japan [228819]...
  29. ncbi request reprint Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing
    D M Livermore
    Antibiotic Resistance Monitoring and Reference Laboratory, Public Health Laboratory Service, 61 Colindale Avenue, London NW9 5HT, UK
    J Antimicrob Chemother 45:205-11. 2000
    ..We conclude that routine susceptibility data for ampicillin, ciprofloxacin, gentamicin and trimethoprim appear sound for E. coli and might be suitable for correlation with other data, e.g. for prescribing...
  30. ncbi request reprint Regional variation in ampicillin and trimethoprim resistance in Escherichia coli in England from 1990 to 1997, in relation to antibacterial prescribing
    D M Livermore
    Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT, UK
    J Antimicrob Chemother 46:411-22. 2000
    ..coli...
  31. ncbi request reprint Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, UK
    J Antimicrob Chemother 46:125-8. 2000
    ..8% of the E. faecium isolates and the single Enterococcus raffinosus isolate were susceptible...
  32. ncbi request reprint Activity of the ketolide telithromycin (HMR-3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, NW9 5HT, London, UK
    Int J Antimicrob Agents 18:73-6. 2001
    ..25 mg/l) was higher than that seen with erythromycin-sensitive isolates. Telithromycin thus appears to be a potentially useful drug in settings where pneumococcal resistance to macrolides is prevalent...
  33. ncbi request reprint Telithromycin. Aventis Pharma
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, London, UK
    Curr Opin Investig Drugs 2:1691-701. 2001
    ..Analysts at Merrill Lynch predicted in November 2001, that the product would be resubmitted in the US in mid-2002, and would make sales of US $5 million in 2001, rising to US $250 million in 2004...
  34. ncbi request reprint Anti-MRSA cephalosporins Bristol-Myers Squibb
    A P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, London, UK
    Curr Opin Investig Drugs 2:205-8. 2001
    ..007 to 2 microM, and improved in vivo stability in human plasma [258890]...
  35. doi request reprint Infection-related mortality in children with malignancy in England and Wales, 2003-2005
    Jessica Bate
    St George s University of London, Paediatric Infectious Diseases Unit, Cranmer Terrace, London, UK
    Pediatr Blood Cancer 53:371-4. 2009
    ..The aim of this study is to describe the infections contributing to deaths in children under 15 years with malignancy in England and Wales in the period 2003-2005...
  36. doi request reprint Changes in clinical indications for community antibiotic prescribing for children in the UK from 1996 to 2006: will the new NICE prescribing guidance on upper respiratory tract infections just be ignored?
    P L Thompson
    Centre for Paediatric Pharmacy Research, School of Pharmacy, London, UK
    Arch Dis Child 94:337-40. 2009
    ..Study..
  37. pmc Trends in fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999
    David M Livermore
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, 61 Colindale Avenue, London NW9 5HT, UK
    Emerg Infect Dis 8:473-8. 2002
    ..1% in 1990 to 10.5% in 1996 and 10.9% in 1999. For both Klebsiella and Enterobacter spp., most resistance was localized in a few centers. Resistance was infrequent and scattered in P. mirabilis, but reached a prevalence of 3.3% in 1999...
  38. ncbi request reprint Isolation and antimicrobial sensitivities of Kluyvera spp. from humans in England, Wales and Northern Ireland, 2005-2006
    Berit Muller-Pebody
    Int J Antimicrob Agents 30:371-2. 2007
  39. pmc In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci
    Alan P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London NW9 5HT, United Kingdom
    Antimicrob Agents Chemother 46:321-6. 2002
    ..015 to 0.5 microg/ml. RWJ-54428 did not select resistant mutants of MRSA or enterococci in challenge experiments and has the potential to be useful for the treatment of infections caused by gram-positive cocci...
  40. ncbi request reprint Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors
    David M Livermore
    Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
    Int J Antimicrob Agents 28:273-9. 2006
    ..Stabilisation or decline in penicillin resistance has occurred in Ireland despite stable or increasing oral beta-lactam sales...
  41. ncbi request reprint Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England
    Nicola A C Potz
    Healthcare Associated Infection and Antimicrobial Resistance Department, Health Protection Agency Centre for Infections 61 Colindale Avenue, London NW9 5EQ, UK
    J Antimicrob Chemother 58:320-6. 2006
    ..To investigate the molecular epidemiology of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in London and South-East England...
  42. ncbi request reprint In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci
    Alan P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London NW9 5HT, UK
    J Antimicrob Chemother 50:89-93. 2002
    ..AZD2563 was equally active against the surveillance isolates and those that had been selected for their multiresistance to other agents. The MICs of AZD2563 were either the same as those of linezolid or two-fold lower...
  43. ncbi request reprint Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002
    Kevin A Fenton
    Communicable Disease Surveillance Centre, Health Protection Agency, London, UK
    Lancet 361:1867-9. 2003
    ..These findings suggest that national and local treatment guidelines need to be reviewed urgently...
  44. ncbi request reprint Characterization of group B streptococci recovered from infants with invasive disease in England and Wales
    Abbie M Weisner
    Streptococcus and Diphtheria Reference Unit, Respiratory and Systemic Infection Laboratory, Health Protection Agency, Colindale, London, United Kingdom
    Clin Infect Dis 38:1203-8. 2004
    ..A trivalent vaccine containing capsular polysaccharides III, Ia, and V could theoretically provide coverage against 85% of the cases of GBS disease among infants in England and Wales...
  45. ncbi request reprint Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods
    Shazad Mushtaq
    Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Colindale, 61 Colindale Avenue, London NW9 5HT, UK
    J Antimicrob Chemother 54:617-20. 2004
    ..Dalbavancin is a long-half-life (9-12 days) glycopeptide, now in Phase 3 development. Its pharmacokinetics may facilitate home intravenous therapy, early discharge and long prophylaxis...
  46. ncbi request reprint Low in vitro selection frequencies of enterococcal and staphylococcal mutants resistant to the oxazolidinone AZD2563
    Mark W Stockdale
    Antibiotic Resistance Monitoring and Reference Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency Colindale, 61 Colindale Ave, London NW9 5HT, UK
    Int J Antimicrob Agents 23:88-91. 2004
    ..Mutants of one E. faecalis isolate had a G2576-->U 23S rRNA mutation; mutants derived from the second E. faecalis isolate lacked this mutation...
  47. ncbi request reprint Linezolid-resistant enterococci: report of the first isolates in the United Kingdom
    Cressida Auckland
    Southampton Public Health Laboratory, Southampton General Hospital, Southampton SO16 6YD, UK
    J Antimicrob Chemother 50:743-6. 2002
    ....
  48. ncbi request reprint Glycopeptide-resistant Staphylococcus aureus
    Alan P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Colindale, London NW9 5HT
    J Antimicrob Chemother 50:621-3. 2002
  49. ncbi request reprint Antimicrobial resistance of invasive Streptococcus pneumoniae isolates in a British district general hospital: the international connection
    Andrew Birtles
    Respiratory and Systemic Infection Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, London NW9 5HT, UK
    J Med Microbiol 53:1241-6. 2004
    ....
  50. ncbi request reprint A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics
    Hazel M Aucken
    Laboratory of Hospital Infection, Central Public Health Laboratory, Colindale, London NW9 5HT, UK
    J Antimicrob Chemother 50:171-5. 2002
    ..The six non-EMRSA-17 isolates identified in the study were sensitive to fusidic acid and rifampicin, and came from six geographically diverse hospitals including three in Northern Ireland...
  51. ncbi request reprint AZD-2563 AstraZeneca
    Alan P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, London, UK
    Curr Opin Investig Drugs 3:848-52. 2002
    ..In October 2001, Morgan Stanley estimated launch in 2004 with sales of US $20 million in that year, rising to US $46 million in following years [429700]...
  52. ncbi request reprint Susceptibility of pneumococci causing meningitis in England and Wales to first-line antimicrobial agents, 2001-2004
    Alan P Johnson
    J Antimicrob Chemother 56:1181-2. 2005
  53. ncbi request reprint Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion
    Jeremy W Tomlinson
    Division of Medical Sciences, Queen Elizabeth Hospital, University of Birmingham, B15 2TH, United Kingdom
    J Clin Endocrinol Metab 87:57-62. 2002
    ..This observation may help to explain individual susceptibility to the adverse effects of glucocorticoids...
  54. ncbi request reprint The future prospects of oxazolidinones
    Alan P Johnson
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London, NW9 5HT, UK
    IDrugs 6:240-5. 2003
    ....
  55. ncbi request reprint The increasing problem of cephalosporin resistance mediated by extended-spectrum beta-lactamases
    Alan P Johnson
    Curr Opin Investig Drugs 5:133-4. 2004